David Reese, Amgen

Am­gen spot­lights pre­clin­i­cal 'mul­ti-specific­s' as an­a­lyst pre­dicts late-stage M&A

If David Reese gets his way, Lumakras will be the first of many Am­gen drugs that shat­ter the fences cur­rent­ly cor­don­ing off vast swaths of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.